Stock Price Update, Recognitions, and Grant of Stock Options - Research Report on Cyberonics, Hill-Rom Holdings, Bio-Reference

Stock Price Update, Recognitions, and Grant of Stock Options - Research Report
     on Cyberonics, Hill-Rom Holdings, Bio-Reference Laboratories, Avanir
                        Pharmaceuticals, and ImmunoGen

Editor Note: For more information about this release, please scroll to bottom.

PR Newswire

NEW YORK, November 21, 2013

NEW YORK, November 21, 2013 /PRNewswire/ --

Today, Analysts' Corner announced new research reports highlighting Cyberonics
Inc. (NASDAQ: CYBX), Hill-Rom Holdings, Inc. (NYSE: HRC), Bio-Reference
Laboratories Inc. (NASDAQ: BRLI), Avanir Pharmaceuticals (NASDAQ: AVNR), and
ImmunoGen Inc. (NASDAQ: IMGN). Today's readers may access these reports free
of charge - including full price targets, industry analysis and analyst
ratings - via the links below.

Cyberonics Inc. Research Report

On November 18, 2013, Cyberonics Inc.'s (Cyberonics) stock increased by 2.83%,
ending the day at $61.42 per share. Over the past three trading sessions, the
Company's stock went up by 2.93%, compared to the Dow Jones Industrial Average
Index, which went up by 0.98% during the same period. The Full Research Report
on Cyberonics Inc. - including full detailed breakdown, analyst ratings and
price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/ad51_CYBX

--

Hill-Rom Holdings, Inc. Research Report

On November 18, 2013, Hill-Rom Holdings, Inc.'s (Hill-Rom Holdings) stock was
up by 0.27%, closing the day at $41.39 per share. Hill-Rom Holdings' stock was
up by 0.17% over the previous three day trading sessions, compared to the S&P
500 Index, which gained 0.53% within the same period. The Full Research Report
on Hill-Rom Holdings, Inc. - including full detailed breakdown, analyst
ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/777e_HRC

--

Bio-Reference Laboratories Inc. Research Report

On November 18, 2013, Bio-Reference Laboratories Inc.'s (Bio-Reference
Laboratories) stock closed at $35.93 per share, marking an increase of 2.69%.
In the last three trading sessions, the Company's stock declined by 0.03%,
compared to the NASDAQ composite Index, which also went down by 0.42% during
the same period. The Full Research Report on Bio-Reference Laboratories Inc. -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/1f59_BRLI

--

Avanir Pharmaceuticals Research Report

On November 8, 2013, Avanir Pharmaceuticals announced that it approved the
grant of stock options to new employees to purchase a total of 202,400 shares
of common stock in the aggregate, on November 5, 2013. According to the
Company, the stock options were granted as inducements material to the new
employees entering into employment, with the Company, as permitted under
NASDAQ Listing Rule 5635(c)(4). Additionally, Avanir Pharmaceuticals stated
that it has granted seven new employees an option to purchase shares of the
Company's common stock with an exercise price of $4.17 per share. The Full
Research Report on Avanir Pharmaceuticals - including full detailed breakdown,
analyst ratings and price targets - is available to download free of charge
at:

http://www.analystscorner.com/r/full_research_report/2ee8_AVNR

--

ImmunoGen Inc. Research Report 

On November 17, 2013, ImmunoGen Inc. (ImmunoGen) announced that the Company
has been once again recognized as one of The Boston Globe's Top Places to
Work. According to the Company, the Boston Globe's 2013 Top Places to Work
survey, which was conducted by WorkplaceDynamics, measured responses of
employees from numerous organizations in Massachusetts, based on six key
factors that contribute to employee happiness, including company direction,
execution, employee connection, workload and responsibility, management and
pay and benefits. Commenting on the achievement, Daniel Junius, President and
CEO of ImmunoGen stated, "ImmunoGen is focused on developing and advancing
meaningful new treatments for cancer. To succeed in this mission, it is
essential that we hire and retain top quality people. We are extremely pleased
that our supportive culture and other key aspects of working at ImmunoGen are
reflected in the survey responses and that our company has again been
recognized as one of The Boston Globe's Top Places to Work." The Full Research
Report on ImmunoGen Inc. - including full detailed breakdown, analyst ratings
and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/11c8_IMGN

----

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by Namrata Maheshwari, a CFA charterholder. However, we
    are only human and are prone to make mistakes. If you notice any errors or
    omissions, please notify us below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Namrata Maheshwari,
CFA, has only reviewed the information provided by Equity News Network in this
article or report according to the Procedures outlined by Equity News Network.
Equity News Network is not entitled to veto or interfere in the application of
such procedures by the outsourced provider to the articles, documents or
reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
Institute.

AnalystsCorner.com

SOURCE Analysts' Corner

Contact: Joe Thomas; +1-310-496-8071 (North America)
 
Press spacebar to pause and continue. Press esc to stop.